What is Cellomics Technology?
Cellomics Technology, LLC is a specialized entity focused on developing cutting-edge tools for gene editing and delivery, with a particular emphasis on mammalian cell gene engineering. The company's comprehensive product portfolio includes a diverse array of lentiviral vectors, essential cell culture reagents, and bespoke services tailored for gene targeting and the generation of stable cell lines. Cellomics Technology is dedicated to empowering researchers in somatic and stem cell genetic engineering by providing high-quality products and expert services, catering to scientists and investigators within the molecular biology and genetic engineering disciplines.
How much funding has Cellomics Technology raised?
Cellomics Technology has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2024): $150K with participation from Bank of America
Key Investors in Cellomics Technology
Bank of America
Bank of America is a leading global financial institution that provides a wide range of banking, investing, asset management, and other financial and risk management products and services. Their participation suggests a debt financing component, supporting Cellomics Technology's operational growth and capital expenditure needs.
What's next for Cellomics Technology?
The substantial large-scale late-stage funding indicates Cellomics Technology is poised for significant expansion and market penetration. This capital infusion is expected to accelerate product development, enhance manufacturing capabilities, and broaden the company's reach within the global research community. The strategic nature of the recent investment suggests a strong alignment with the company's long-term vision, potentially enabling new research initiatives and the commercialization of novel gene editing technologies. Cellomics Technology is well-positioned to solidify its role as a key player in advancing genetic engineering solutions.
See full Cellomics Technology company page
